A large study of nearly 2,200 pregnancies found that women who delivered early carried more misfiring immune proteins in their blood than women who carried to term.
Story Snapshot
- Researchers studied blood from 2,194 pregnancies across eight groups and found higher overall autoantibody activity in preterm births.
- One specific antibody, aimed at a protein called IL1RA, showed up in about 7% of preterm pregnancies.
- Scientists confirmed the blood findings by testing placental tissue in the lab, giving the result extra weight.
- Earlier, smaller studies have linked other antibodies, including ones tied to folate and tissue rejection, to early birth risk.
What The New Study Actually Found
The study, titled “Evidence for Maternal Autoantibodies in the Pathogenesis of Preterm Birth,” pulled blood samples from eight separate pregnancy groups. Across all of them, women who gave birth early showed broader autoantibody activity than women who delivered at term. That means their immune systems were producing more antibodies that attack the body’s own proteins, not just germs or viruses.
One antibody stood out. It targets IL1RA, a protein that normally calms down inflammation driven by a molecule called IL-1β. Researchers found this antibody enriched in roughly 7% of preterm pregnancies. That is a minority, but it is a clear, repeatable signal, not a fluke buried in noise.
Confirmed Twice, Not Just Once
What separates this research from a typical blood-test survey is the second check. Scientists did not stop at counting antibodies in serum. They went to placental tissue itself, using a lab technique called immunoprecipitation paired with mass spectrometry, essentially fishing out the exact proteins the antibodies were attacking. The placental results matched the blood results, which strengthens confidence the signal is real.
The pattern also showed up broadly, not in one rare corner of preterm birth. It appeared in spontaneous early labor and in extremely early preterm births, and it grew stronger with each pregnancy a woman had carried before. That spread matters, because it suggests the antibody problem is not tied to one narrow medical condition.
This Fits A Pattern Scientists Have Chased For Years
This is not the first time researchers have pointed at a woman’s own immune system as a possible driver of early labor. An earlier study found folate-receptor antibodies in 65.2% of women with preterm births, compared to 28% of women who carried to term, with the odds of preterm birth roughly five times higher in antibody-positive women.
Another study looked at anti-HLA antibodies, which relate to tissue rejection, and found them in 48.6% of spontaneous preterm births versus 32.1% of term births. Taken together with the new IL1RA findings, a picture is forming where the mother’s immune system, in certain women, may turn against proteins essential for keeping a pregnancy on schedule.
Why This Isn’t A Single Simple Answer
Preterm birth is not one disease with one cause. Doctors split it into three types: labor that starts on its own, early rupture of the membranes, and early delivery ordered by a doctor for the mother or baby’s safety. Known drivers include infection, placental blood flow problems, an overstretched uterus, and chronic stress, often overlapping in the same pregnancy.
That complexity explains why antibody research has produced mixed results in other areas. Thyroid antibodies, for instance, showed no link to early delivery before 35 weeks in one study, while a much larger 40,214-woman study found no overall risk increase either, though one antibody subgroup still stood out. The new IL1RA finding adds a specific, biologically confirmed piece to a much larger puzzle, not a final answer.
Where The Research Still Needs To Go
Because the IL1RA signal only appeared in about 7% of preterm cases, researchers still need to test whether blocking or removing that antibody actually prevents early labor, rather than just riding alongside it. That kind of controlled testing has not yet happened in humans, so a cause-and-effect claim is not yet proven.
Future work will need to confirm the signal in new, independent groups of women before any doctor could use it as a screening tool. Until then, this study offers a genuinely promising clue about one hidden driver of preterm birth, not a ready-made test or treatment for expecting mothers today.
Maternal autoantibodies in term pregnancy & preceding preterm delivery, including anti-IL1RA, may have direct pathogenic consequences @NatImmunol https://t.co/FvCWnQ3wY6 @derisij @UCSF pic.twitter.com/pir2VTGu6U
— Waggoner Lab (@LabWaggoner) October 14, 2026
For families who have lived through early birth without a clear explanation, findings like these matter. They point toward real biology instead of guesswork, and they give researchers a concrete target, IL1RA, worth chasing in the years ahead.
Sources:
youtube.com, pubmed.ncbi.nlm.nih.gov, dspace.library.uu.nl, bmj.com
